Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Survodutide is a candidate drug in the obesity treatment pipeline, belonging to a class of dual GLP-1 and GCGR agonists
It is not a guide for human or veterinary use and does not provide medical, clinical, dietary, or treatment advice
Because AOD 9604 does not bind the growth hormone receptor, it does not trigger the IGF-1 cascade
The vitamin deficiency concern arises from how GLP-1 receptor agonists alter gastric physiology
Specific effects depend on dose, format, individual factors, and concurrent interventions
US$ 26.17
US$ 23.87
US$ 22.26
